Polyarticular juvenile idiopathic arthritis

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

1 event
Sep 2020

SIMPONI ARIA®: FDA approved

treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

3 programs

FINANCIAL LANDSCAPE SUMMARY

3

Total programs

3

Open now

1

Copay cards

Copay Assistance1

SIMPONI ARIA�

Janssen Research & Development, LLC

OpenContact for details

Patient Assistance Programs2

HUMIRA

AbbVie, Inc.

OpenContact for detailsApply ↗

Orencia

Bristol-Myers Squibb Co.

OpenContact for detailsApply ↗

View all support programs on disease page →

Approved Treatments

5 FDA-approved

SIMPONI ARIA�

(golimumab)Orphan drug

Janssen Research & Development, LLC

Tumor Necrosis Factor Blocker [EPC]

12.1 Mechanism of Action Golimumab is a human monoclonal antibody that binds to both the soluble and transmembrane bioactive forms of human TNFα. This...

Approved Sep 2020FDA label ↗

Enbrel

(etanercept)Orphan drugstandard

Immunex Corporation

Tumor Necrosis Factor Blocker [EPC]

12.1 Mechanism of Action TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. It plays an important rol...

FDA label ↗

Orencia

(abatacept)Orphan drugstandard

Bristol-Myers Squibb Co.

Selective T Cell Costimulation Modulator [EPC]

12.1 Mechanism of Action Abatacept, a selective costimulation modulator, inhibits T-cell (T lymphocyte) activation by binding to CD80 and CD86, thereb...

FDA label ↗

Actemra

(tocilizumab)Orphan drugstandard

Genentech, Inc.

Interleukin-6 Receptor Antagonist [EPC]

12.1 Mechanism of Action Tocilizumab binds to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R), and has been shown to inhibit IL-6-m...

FDA label ↗

HUMIRA

(adalimumab)Orphan drugstandard

AbbVie, Inc.

12.1 Mechanism of Action Adalimumab binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors. Adalim...

FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for Polyarticular juvenile idiopathic arthritis.
Search all trials →
Search clinical trials for Polyarticular juvenile idiopathic arthritis

Recent News & Research

No recent news articles indexed yet for Polyarticular juvenile idiopathic arthritis.
Search PubMed for Polyarticular juvenile idiopathic arthritis

Browse all Polyarticular juvenile idiopathic arthritis news →

Specialist Network

Top 6 by expertise

View all Polyarticular juvenile idiopathic arthritis specialists →

Quick Actions